位元堂2026年报

Contents Corporate Information BOARD OF DIRECTORS Executive Directors Mr. Tang Ching Ho,GBS, JP,ChairmanMs. Tang Wai ManMs. Law Man Yee, Anita Independent Non-executive Directors Mr. Li Ka Fai, David,MHProfessor Sit Wing Hang,GBS, JPProfessor Chan Wing Kwong,MD AUDIT COMMITTEE Mr. Li Ka Fai, David,MH,ChairmanProfessor Sit Wing Hang,GBS, JPProfessor Chan Wing Kwong,MD REMUNERATION COMMITTEE Professor Sit Wing Hang,GBS, JP,ChairmanProfessor Chan Wing Kwong,MDMr. Li Ka Fai, David,MHMr. Tang Ching Ho,GBS, JPMs. Tang Wai Man NOMINATION COMMITTEE Professor Chan Wing Kwong,MD,ChairmanMr. Li Ka Fai, David,MHProfessor Sit Wing Hang,GBS, JPMr. Tang Ching Ho,GBS, JPMs. Tang Wai Man EXECUTIVE COMMITTEE Mr. Tang Ching Ho,GBS, JP,ChairmanMs. Tang Wai ManMs. Law Man Yee, Anita Corporate Information(Continued) AUTHORISED REPRESENTATIVES Under Listing RulesMr. Tang Ching Ho,GBS, JPMs. Ng Yee Man Fiona COMPANY SECRETARY Ms. Ng Yee Man Fiona LEGAL ADVISERS • Reed Smith Richards Butler LLPGallantSullivan & Cromwell (Hong Kong) LLP AUDITOR Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor under theAccounting and Financial Reporting Council Ordinance PRINCIPAL BANKERS United Overseas Bank Limited, Hong Kong BranchTaiwan Shin Kong Commercial Bank Co., LtdCTBC Bank Co., Ltd.DBS Bank (Hong Kong) LimitedThe Hongkong and Shanghai Banking Corporation Limited REGISTERED OFFICE Clarendon House2 Church StreetHamilton HM 11Bermuda(up to 2 August 2026) Clarendon House2 Church StreetHamilton HM 11Bermuda Richmond House12 Par-la-Ville RoadHamilton HM08Bermuda(from 3 August 2026) Richmond House12 Par-la-Ville RoadHamilton HM08Bermuda Corporate Information(Continued) HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS INHONG KONG Suite 3101, 31/F., Skyline Tower39 Wang Kwong RoadKowloon BayKowloonHong Kong 39313101 PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE INBERMUDA Appleby Global Corporate Services (Bermuda)LimitedCanon’s Court, 22 Victoria StreetPO Box HM 1179, Hamilton HM EXBermuda Appleby Global Corporate Services (Bermuda) Limited Canon’s Court, 22 Victoria StreetPO Box HM 1179 Hamilton HM EXBermuda BRANCH SHARE REGISTRAR AND TRANSFER OFFICE INHONG KONG 䢭1617 Tricor Investor Services Limited17/F., Far East Finance Centre16 Harcourt RoadHong Kong BOARD LOT 5,000 5,000 shares pr@waiyuentong.com http://www.wyth.net http://www.wyth.net STOCK CODE 897 897 Chairman’s Statement Authentic Herbal Medicine In constant pursuit of excellence over the past 129 years, Wai Yuen Tong haswithstood a century with established reputation in providing Chinese andWestern pharmaceutical products and traditional Chinese medicine outpatientclinic services. I hereby express my heartfelt gratitude to all colleagues for their dedicationduring the past challenging year in the inheritance of tradition, and contributionto the health of people in the community. To all Shareholders, On behalf of the board of directors (the “Board” or the “Directors”)of Wai Yuen Tong Medicine Holdings Limited (the “Company” andtogether with its subsidiaries, the “Group”), I am pleased to present toyou the annual report for the year ended 31 March 2026 (the “Year” orthe “Year under Review”). Since its establishment in 1897, Wai YuenTong has always adhered to its core philosophy of “Preparing Medicinewith Dedication, Growing Strong with Reputation”. We are committedto passing down the profound wisdom of traditional Chinese medicine(“TCM”), making the TCM industry go global, and leading the industryin setting higher standards, with a view to providing comprehensive andexquisite medical products and services to each customer. BUSINESS REVIEW Currently, the Group owns the widely recognized Chinese pharmaceuticaland health food brand “Wai Yuen Tong” through Wai Yuen TongMedicine Company Limited (“Wai Yuen Tong” or “WYT Medicine”),and holds the internationally renowned Western pharmaceutical brands“Madame Pearl’s” and “Pearl’s” through Luxembourg Medicine CompanyLimited (“Luxembourg Medicine”, together with its subsidiaries, the“Luxembourg Medicine Group”). The Group’s Chinese and Westernpharmaceutical and healthcare businesses are developing synergistically,forming a positive interaction. During the Year under Review, despite the uneven pace of recoveryin the local consumer market and fluctuations in the macroeconomicenvironment, the TCM industry demonstrated unique resilience andstructural growth opportunities. This was driven by the acceleration ofpopulation aging, increasing public emphasis on “preventive medicine”and sub-health management, and the streamlined approval process forTCM in the Greater Bay Area. Consumers are paying more attention todaily health management and high-quality TCM conditioning services,driving a steady increase in demand for health products and proprietaryChinese medicines. The Company’s market share and leading positionhave been further strengthened due to its flexible response